Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

Table 2 Unadjusted incidence rates of venous thromboembolic events, before and after STS diagnosis

n = 3,480 STS^a patients	Incidence 12 months before STS diagnosis	Incidence 12 months after STS diagnosis
DVT^a
n/person-years^b	137/3,418	367/2,468
Rate/1,000^c	40.1 (33.7–164.7)	148.7 (133.9–164.7)
Rate ratio (after vs. before)^d	–	3.7 (3.0–4.5)
PE^a
n/person-years^b	34/3,463	105/2,589
Rate/1,000^c	9.8 (6.8–49.1)	40.6 (33.2–49.1)
Rate ratio (after vs. before)^d	–	4.1 (2.8–6.1)
OTE^a
n/person-years^b	82/3,438	106/2,590
Rate/1,000^c	23.9 (19.0–49.5)	40.9 (33.5–49.5)
Rate ratio (after vs. before)^d	–	1.7 (1.3–2.3)

Rate ratios are highlighted in italics.
^a VTE venous thromboembolic events, STS soft tissue sarcoma, DVT deep vein thrombosis, PE pulmonary embolism, OTE other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd–Chiari syndrome, and venous embolism/thrombosis of renal vein.
^b n number of VTE events, p-y person-years.
^cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation (ages 65+) of STS patients. Only first VTE counted in rate estimates.
^dRate ratios are unadjusted.

ISSN: 2045-3329